Navigation Links
Gonorrhea Resistant to All But One Antibiotic: CDC
Date:8/9/2012

By Amanda Gardner
HealthDay Reporter

THURSDAY, Aug. 9 (HealthDay News) -- With options shrinking to a single antibiotic that can fight resistant strains of gonorrhea, U.S. health authorities issued revised guidelines for treating the sexually transmitted bacteria on Thursday.

The U.S. Centers for Disease Control and Prevention now recommends that the injectable antibiotic Rocephin (ceftriaxone) be the first-line treatment for this sexually transmitted disease, supplanting Suprax (cefixime).

Rocephin should be used in combination with one of two oral antibiotics: azithromycin or doxycycline, the CDC stated in the guidelines published in the Aug. 10 issue of the Morbidity and Mortality Weekly Report.

Strains of gonorrhea that are resistant to Suprax have increased globally.

"We are very concerned about the possibility of the potential for untreatable gonorrhea," said Dr. Robert Kirkcaldy, a medical epidemiologist with the CDC's Division of STD Prevention. "Facing this threat of drug resistance, the CDC is taking the critical step to preserve the last remaining drug that we know to be effective. We're hoping that the actions taken now will prevent that from becoming a reality."

Another expert agreed with the decision. "The risk of organisms becoming completely resistant will be a lot less [with the combination of two drugs] than if we're just doing one treatment," said Dr. Greg Ward, an assistant professor of obstetrics, gynecology and women's health at Saint Louis University, in St. Louis. "Two antibiotics confuses the organism a little bit so . . . this should slow the progression of resistance."

Neisseria gonorrhoeae is a particularly "crafty" bacteria which has progressively become resistant to every antibiotic used against it since the 1930s, Kirkcaldy said.

These include sulfonamides, penicillin, tetracycline and, in the 2000s, fluoroquinolones.

In 2007, the CDC recommended abandoning fluoroquinolones as a first-line treatment, thus leaving cephalosporins, which include Suprax and Rocephin, as the only class of antibiotics available to effectively combat gonorrhea.

By limiting use of cephalosporins to just Rocephin, it's hoped that gonorrhea will not develop resistance to all drugs in the class.

Although rates of gonorrhea are at historic lows, Kirkcaldy said, it is still the second most commonly recorded infection with more than 700,000 new U.S. cases annually.

Symptoms can include burning when urinating or a discharge from the penis or the vagina. But too often, gonorrhea produces no symptoms at all.

"If left untreated, gonorrhea can result in severe reproductive health consequences including chronic pelvic pain, potentially life-threatening ectopic pregnancy and infertility," Kirkcaldy said. "We also know that having this infection can increase risk of acquiring or transmitting HIV."

The new recommendations also call for all patients to undergo a "test of cure" to ensure that the infection is fully resolved. That means all patients receiving treatment will need to make another office visit, Ward said.

In the past, the test of cure was only done on pregnant women, he added.

To prevent transmission of gonorrhea, individuals should also follow safe-sex practices, such as using condoms. Noting that abstinence and monogamy are the greatest protective measures, the CDC said that groups at greatest risk -- sexually active gay and bisexual men and high-risk sexually active women -- should be tested for gonorrhea at least once a year.

Kirkcaldy also called on drug makers to "step up quickly and boldly to invest in new drugs" to fight gonorrhea.

More information

The U.S. Centers for Disease Control and Prevention has more on gonorrhea.

SOURCES: Robert Kirkcaldy, M.D., medical epidemiologist, Division of STD Prevention, U.S. Centers for Disease Control and Prevention; Greg Ward, M.D., assistant professor of obstetrics, gynecology and women's health, Saint Louis University, St. Louis; Aug. 10, 2012, Morbidity and Mortality Weekly Report


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Antibiotic-Resistant Gonorrhea Spreading: WHO
2. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
3. Computational analysis identifies drugs to treat drug-resistant breast cancer
4. A new route for tackling treatment-resistant prostate cancer
5. Abuse-Resistant Oxycontin May Be Driving Addicts to Heroin
6. Scientists develop new strategy to overcome drug-resistant childhood cancer
7. Rare Drug-Resistant Bacteria Spotted in U.S. Hospital
8. New Medicine Might Fight Drug-Resistant TB, Study Says
9. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
10. New drug strategy attacks resistant leukemia and lymphoma
11. Kinase test may yield big gains for drug-resistant cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC is pleased ... professionals throughout the country. The Guard was specifically designed to handle each element ... training, regulatory updates, and compliance coaching. , In addition to meeting the compliance ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Gout is ... and brings pain that is often severe, with intense swelling and redness. It is ... eight million people, but older adults are the most susceptible, according to the February ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association ... inspirational speaker Jan Fox will serve as keynote speaker at the organization’s 2016 ... with tools to more effectively communicate with their own organizational staff and leadership. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 Urologix, the market leader for in-office ... Prostatic Hyperplasia (BPH), announces new private ownership and is ... medical device industry veteran of more than 20 years, ... Plymouth, Minn. The ... and Prostiva® RF Therapy, will continue to be broadly ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: